CA-THE-OPEN-GROUP
6.1.2022 10:02:04 CET | Business Wire | Press release
Effective January 1st, Energistics Consortium, Inc. is now an affiliate of The Open Group®, a global consortium that enables the achievement of business objectives through technology standards. Energistics remains a separate entity, with The Open Group assuming control of Energistics operations, in a move which will enable broader community access, more efficient collaboration, and stronger standards evolution in line with the global energy transition.
Having proudly served the industry for over thirty years, Energistics is also a long-standing member of The Open Group OSDU™ Forum, and in October 2018 became the first non-operator company to be invited to join the Forum. Its WITSML™ , RESQML™ , PRODML™ , and ETP standards have become universal in the industry and form a critical component of the OSDU Data Platform.
Development will continue in Energistics Special Interest Groups (SIGs) to ensure the standards remain a vibrant part of the Energy community. Most recently, Energistics Transfer Protocol v1.2 was released in September 2021, and a consolidated Release Candidate for new versions of RESEQML, PRODML, and WITSML was made available in December 2021.
This work will support both the wider industry and the ongoing development of the OSDU Data Platform and standards for analyzing legacy subsurface energy data as well as new energy data from wind, geothermal, hydrogen, photovoltaic sources, and carbon capture, utilization, and storage data sources.
“As Energistics starts an exciting new chapter in its development, we want to thank the more than 3,500 upstream subject matter experts, from over 115 member companies, who have contributed to its development over the last thirty years,” said Ross Philo, CEO of Energistics. “We are also particularly grateful to our operational staff, who have served the industry with outstanding dedication. They have ensured a smooth transition for our members, and we wish them all the best in their next adventure.”
Today’s transition of governance reflects the significant overlap between Energistics and The Open Group OSDU Forum, with 42 of the 220 current Forum members also being Energistics members. Retaining its own board, the work of Energistics will now be overseen by members of both organizations alongside The Open Group itself.
“The relationship between Energistics and The Open Group has been a long and fruitful one, and this is the right next step for our organizations,” adds Steve Nunn, CEO and President of The Open Group. “Bringing the knowledge and capabilities of The Open Group OSDU Forum and the Energistics SIGs closer together means that we will continue to lead the charge in data exchange standards for the industry, while also opening doors to a broader community for both organizations. We are committed to ensuring that the Energistics standards continue to evolve, thrive, and enable cross-discipline integration of industry data.”
- ENDS -
About Energistics
Energistics is the leading upstream oil and gas industry's data standards body. We are a global, non-profit consortium established over 30 years ago to bring together industry professionals in a neutral and collaborative environment to develop and deploy open data exchange standards and to address oil and gas information sharing challenges. Our members consist of international and nationalized oil companies, oilfield service companies, hardware and software vendors, system integrators, regulatory agencies, and the global standards user community. For more information, visit our website at www.energistics.org .
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 850 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .
About The Open Group OSDU Forum
The Open Group OSDU Forum is developing the Open-Source Software OSDU Data Platform and associated standards that enables the Energy industry to develop the transformational technology implementation to support the world's changing Energy needs. The Open Group OSDU Forum has over 225 member organizations and over 1900 subscribers worldwide. Membership in The Open Group OSDU Forum is available to all energy stakeholders including international and nationalized oil companies, new energy providers, application developers, service operators, technology providers, software companies, academia, and more. More information on the OSDU Forum can be found at www.osduforum.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005072/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
